Skip to main content

Tofacitinib, Disease-Modifying Anti-Rheumatic Drugs (DMARDs) and Tumor Necrosis Factor Inhibitors (TNFi) Use: A Descriptive Analysis

    Basic Details
    Date Posted
    Medical Product
    disease-modifying anti-rheumatic drugs (DMARDs)
    tumor necrosis factor inhibitors (TNFi)

    In this report we examined characteristics of patients receiving disease-modifying anti-rheumatic drugs (DMARDs), tumor necrosis factor inhibitors (TNFi), or tofacitinib in the Sentinel Distributed Database (SDD) along with switching patterns observed between these exposures.

    The study period includes data from November 1, 2012 to September 30, 2019. We distributed this request to 16 Sentinel Data Partners on February 25, 2020.

    Additional Details
    FDA Center
    Time Period
    November 1, 2012 - September 30, 2019
    Analysis Type
    Population / Cohort
    Individuals 18 years of age and older
    Data Sources
    Sentinel Distributed Database (SDD)